Image

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

Recruiting
18-79 years
All
Phase N/A

Powered by AI

Overview

This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.

Description

The study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.

The Vertex Pulmonary Embolectomy System is intended for the non-surgical removal of emboli and thrombi from blood vessels as a means for treating pulmonary embolism.

Eligibility

Inclusion Criteria

  1. Age ≥ 18 years < 80 years
  2. Acute onset of symptoms ≤ 14 days consistent with the presence of pulmonary embolism.
  3. CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
  4. RV/LV ratio of > 0.9 on CTA as assessed by investigator (site determined).
  5. Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
  6. Subject or subject's legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care Protocol-specific procedures
  7. Subject is willing and able to comply with all Protocol-required follow-up visits

Exclusion Criteria

  1. Thrombolytic use within 30 days of baseline CTA
  2. Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
  3. Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
  4. Unstable heart rate > 130 beats per minute prior to procedure
  5. FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
  6. Hematocrit < 28%
  7. Platelets < 100,000/μL
  8. Serum baseline creatinine > 1.8 mg/dL
  9. International normalized ratio (INR) > 3
  10. Major trauma injury severity score (ISS) > 15 within the past 14 days
  11. Presence of intracardiac lead in the right ventricle or right atrium placed <180 days prior to the index procedure
  12. Cardiovascular or pulmonary surgery within last 30 days
  13. Actively progressing cancer requiring chemotherapy
  14. Known bleeding diathesis or coagulation disorder
  15. Left bundle branch block
  16. History of severe or chronic pulmonary arterial hypertension
  17. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
  18. History of decompensated heart failure
  19. Patients on extracorporeal membrane oxygenation (ECMO)
  20. History of underlying lung disease that is oxygen dependent
  21. History of chest irradiation
  22. History of heparin-induced thrombocytopenia (HIT)
  23. Contraindication to systemic or therapeutic doses of heparin or anticoagulants
  24. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  25. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention
  26. Life expectancy of < 365 days, as determined by Investigator
  27. Female who is pregnant or nursing
  28. Current participation in another investigational drug or device treatment study
  29. Inability to lay flat for procedure
  30. Known presence of right-to-left cardiac shunt
  31. History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
  32. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis

Study details
    Pulmonary Embolism

NCT06576427

Jupiter Endovascular

13 August 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.